|
Press Releases
All 2008 Releases
 |
Vyteris Announces Growth Initiative Through Expanded Business Development Team
Sep 23, 2008
|
11.1 KB |
|
| |
FAIR LAWN, N.J., Sep 23, 2008 (BUSINESS WIRE) -- Vyteris, Inc. (OTCBB: VYTR), developer and manufacturer of the first FDA-approved active patch transdermal drug delivery system (LidoSite(R)) and a leader in active transdermal drug delivery technology, announced the establishment of its Business Development Team. Vyteris' Business Development Team w...
|
|
Dutton Associates Announces Investment Opinion: Vyteris Rating Speculative Buy In Update By Dutton Associates
Sep 8, 2008
|
8.0 KB |
|
| |
ROSEVILLE, Calif., Sep 08, 2008 (BUSINESS WIRE) -- Dutton Associates updates its coverage of Vyteris (OTCBB:VYTR) maintaining a Speculative Buy rating and a $1 price target. The 13-page report by Dutton senior analyst Richard W. West, CFA is available at www.jmdutton.com as well as from First Call, Bloomberg Professional, FactSet, Capital IQ, Zacks...
|
|
Vyteris Annouces Key Scientific Advisors
Aug 19, 2008
|
11.3 KB |
|
| |
FAIR LAWN, N.J., Aug 19, 2008 (BUSINESS WIRE) -- Vyteris, Inc. (OTCBB: VYTR), manufacturer of the first FDA-approved active patch transdermal drug delivery system and a leader in active transdermal drug delivery technology, announced the formation of a Scientific Advisory Group comprised of four renowned scientists, researchers and clinicians with ...
|
|
Vyteris Announces Launch of Initiative to Pursue Joint Development Agreements in Pain Management
Aug 5, 2008
|
10.2 KB |
|
| |
FAIR LAWN, N.J., Aug 05, 2008 (BUSINESS WIRE) -- Vyteris, Inc. (OTC BB: VYTR), manufacturer of the first U.S. Food and Drug Administration (FDA)-approved active patch transdermal drug delivery system, announced an initiative to identify and target candidate drugs in the pain management field that could potentially be delivered using Vyteris' active...
|
|
Vyteris Announces Successful Completion of Peptide Dose Ranging Study in Preparation for Phase II Human Clinical Trials
Jul 28, 2008
|
10.4 KB |
|
| |
FAIR LAWN, N.J., Jul 28, 2008 (BUSINESS WIRE) -- Vyteris, Inc. (OTC BB: VYTR), manufacturer of the first FDA-approved active patch transdermal drug delivery system, in partnership with Ferring Pharmaceuticals, announced the completion of a Phase I dose ranging study using Vyteris' patented Smart Patch transdermal system for delivery of a peptide ho...
|
|
Vyteris, Inc. Receives $2.5 Million Loan from Ferring Pharmaceuticals, Inc.
Jul 21, 2008
|
9.1 KB |
|
| |
FAIR LAWN, N.J.--(BUSINESS WIRE)--Vyteris, Inc. (OTC BB: VYTR), manufacturer of the first FDA-approved active patch transdermal drug delivery system, received $2.5 million principal amount of financing effective on July 9, 2008 from Ferring Pharmaceuticals, Inc. (“Ferring”), which represented an advance on a potential milestone payment ...
|
|
Vyteris, Inc. Announces Completion of Reverse Stock Split and New Trading Symbol
Jun 17, 2008
|
8.0 KB |
|
| |
FAIR LAWN, N.J.--(BUSINESS WIRE)--Vyteris, Inc. (OTCBB: VYTR - News), manufacturer of the first FDA-approved active patch transdermal drug delivery system, announced implementation of a 1 for 15 reverse split of the company’s common stock, as well as the designation of a new trading symbol by NASDAQ.
The reverse stock split affects all of...
|
|
Vyteris Announces Plans to Pursue Strategy for Transdermal Drug Delivery Technology
Jun 11, 2008
|
10.3 KB |
|
| |
FAIR LAWN, N.J., Jun 11, 2008 (BUSINESS WIRE) -- Vyteris, Inc. (OTCBB: VYHN), manufacturer of the first FDA-approved active patch transdermal drug delivery system, informed its shareholders of important plans to pursue an aggressive partnership and licensing strategy for its transdermal drug delivery technology, as well as restructuring of its boar...
|
|
Vyteris Announces Appointments of President and Chief Financial Officer
May 13, 2008
|
10.8 KB |
|
| |
FAIR LAWN, N.J., May 13, 2008 (BUSINESS WIRE) -- Vyteris, Inc. (OTCBB: VYHN), manufacturer of the first FDA-approved active patch transdermal drug delivery system, discussed the appointments of Haro Hartounian as president and Joseph Himy as chief financial officer to lead the company in its pursuit of several strategic initiatives for collaborativ...
|
|
Vyteris Announces Recent Appointment of Two New Members to Its Board of Directors
May 1, 2008
|
9.9 KB |
|
| |
FAIR LAWN, N.J., May 01, 2008 (BUSINESS WIRE) -- Vyteris, Inc. (OTCBB: VYHN), developer of the first FDA-approved active patch transdermal drug delivery system, announces the appointments of John E. Burrows and Susan P. Guerin to the company's board of directors, both of which became effective earlier in 2008. Burrows serves on the company's audit ...
|
|
Vyteris Announces Redirection of Business Towards the Advancement of Peptide Delivery
Feb 1, 2008
|
10.3 KB |
|
| |
FAIR LAWN, N.J., Feb 01, 2008 (BUSINESS WIRE) -- Following the successful results of a completed Phase 1 clinical trial demonstrating that Vyteris' patented Smart Patch transdermal technology delivered a peptide molecule in humans without the use of needles, Vyteris, with approval from its Board of Directors, has redirected its business to focus on...
|
|
Vyteris Announces First Successful Non-Invasive Delivery of Peptide Using Smart Patch Technology
Jan 22, 2008
|
11.3 KB |
|
| |
FAIR LAWN, N.J., Jan 22, 2008 (BUSINESS WIRE) -- Citing a significant advance in drug delivery, Vyteris, Inc. (OTC BB: VYHN) and Ferring Pharmaceuticals today announced results from a completed Phase 1 clinical trial demonstrating that Vyteris' patented Smart Patch transdermal technology successfully delivered a peptide molecule in humans (multiple...
|
| Showing 1-12 of 12 |
Page: 1 |
|
|
= add release to Briefcase
|
